Cetuximab: Difference between revisions
imported>Howard C. Berkowitz No edit summary |
Pat Palmer (talk | contribs) m (→Drug toxicity) |
||
| Line 12: | Line 12: | ||
==Drug toxicity== | ==Drug toxicity== | ||
[[Drug toxicity]] includes a acneiform papulopustular rash involving the face and trunk in about 10% of patients.<ref | [[Drug toxicity]] includes a acneiform papulopustular rash involving the face and trunk in about 10% of patients.<ref name="pmid18003960">{{cite journal |author=Jonker DJ, O'Callaghan CJ, Karapetis CS, ''et al'' |title=Cetuximab for the treatment of colorectal cancer |journal=N. Engl. J. Med. |volume=357 |issue=20 |pages=2040–8 |year=2007 |pmid=18003960 |doi=10.1056/NEJMoa071834}}</ref><ref name="pmid18784101">{{cite journal| author=Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al.| title=Platinum-based chemotherapy plus cetuximab in head and neck cancer. | journal=N Engl J Med | year= 2008 | volume= 359 | issue= 11 | pages= 1116-27 | pmid=18784101 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=18784101 | doi=10.1056/NEJMoa0802656 }} | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=18784101 | doi=10.1056/NEJMoa0802656 }}</ref> In patients with colorectal cancer<ref name="pmid18003960"/>, but not head and neck cancer<ref name="pmid18784101"/>, this rash is associated with improved survival. | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 10:13, 13 September 2024
In medicine, cetuximab (se tux' i mab) is an antineoplastic agent that is "an antibody that blocks receptors for epidermal growth factor."[1]
Uses
Head and neck cancer
Cetuximab can help treat head and neck cancer; the percentage of cells that are EGFR positive did not seen to predict the response to cetuximab in a randomized controlled trial.[2]
Colorectal cancer
Cetuximab can help treat colorectal cancer in patients whose cancer expressed epidermal growth factor receptor according to a randomized controlled trial.[3] This trial did not include patients whose cancers did not express [epidermal growth factor receptor]].
Drug toxicity
Drug toxicity includes a acneiform papulopustular rash involving the face and trunk in about 10% of patients.[3][2] In patients with colorectal cancer[3], but not head and neck cancer[2], this rash is associated with improved survival.
References
- ↑ Anonymous (2024), Cetuximab (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ 2.0 2.1 2.2 Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al. (2008). "Platinum-based chemotherapy plus cetuximab in head and neck cancer.". N Engl J Med 359 (11): 1116-27. DOI:10.1056/NEJMoa0802656. PMID 18784101. Research Blogging.
Cite error: Invalid
<ref>tag; name "pmid18784101" defined multiple times with different content - ↑ 3.0 3.1 3.2 Jonker DJ, O'Callaghan CJ, Karapetis CS, et al (2007). "Cetuximab for the treatment of colorectal cancer". N. Engl. J. Med. 357 (20): 2040–8. DOI:10.1056/NEJMoa071834. PMID 18003960. Research Blogging.
Cite error: Invalid
<ref>tag; name "pmid18003960" defined multiple times with different content